Fuyuan Pharmaceutical: FY103 Injection Receives Approval Notification for Clinical Trial

2026-03-18 02:14:17

People’s Financial News, March 16 — Fuyuan Pharmaceutical (601089) announced on March 16 that the company has received the approval notice from the National Medical Products Administration for the clinical trial of FY103 injection. The clinical trial will commence soon. FY103 injection is a Class 1 innovative chemical drug developed independently by the company, used for the treatment of hypertension, administered via subcutaneous injection. Currently, there are no approved products of the same type and target in China or abroad.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.